Cure Today12h
Understanding the Benefit of Subcutaneous Versus IV Opdivo in Patients With Solid Tumors
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
BioPharma Dive15h
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results
The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...
STAT22h
With a major patent cliff coming, will JPM play host to some serious deal-making?
The drug industry is facing one of the largest patent cliffs in recent history. Will that mean dealmaking at the annual J.P.